Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Ecuador signs COVID-19 vaccine supply deals with pharma companies

10/21/2020 | 03:49pm EST
FILE PHOTO: Outbreak of the coronavirus disease (COVID-19) in Guayaquil, Ecuador

QUITO (Reuters) - Ecuador has signed supply agreements with major pharmaceutical firms including Pfizer Inc and BioNTech to provide millions of COVID-19 vaccines, the health minister said on Wednesday, adding it is seeking talks with Chinese laboratories for more supplies.

The Andean country, facing an economic downturn exacerbated by the pandemic, has obtained funds through the Inter-American Development Bank to finance access to the COVAX vaccine, which is being led by the World Health Organization, Carlos Zevallos said.

"At this moment we do not have scientific proof, for example, that vaccine X is going to work on a specific population. That is why we are targeting all possibilities," Zevallos told reporters. "We want an effective, safe vaccine that reaches the country on time and at a reasonable price."

The government of President Lenin Moreno has also signed a vaccine supply deal with AstraZeneca Plc and a letter of intent to buy another 2 million doses from COVAXX, a unit of United Biomedical Inc.

And it has begun talks with Johnson & Johnson, Novavax Inc and Moderna Inc, and has notified three Chinese laboratories of its interest in starting conversations.

Ecuador has nearly 155,000 coronavirus infections and more than 8,000 deaths, according to official data.

The government also includes in the data about 4,300 people who have probably died of COVID-19.

Authorities expect the vaccines will begin arriving in 2021, with priority to be given to health professionals and workers at risk of exposure.

(Reporting by Alexandra Valencia in Quito; Writing by Brian Ellsworth; Editing by Matthew Lewis)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.28% 7770 Delayed Quote.2.14%
BIONTECH SE 4.79% 109.99 Delayed Quote.224.65%
MODERNA, INC. 16.35% 127.03 Delayed Quote.549.44%
NOVAVAX, INC. 22.50% 125.69 Delayed Quote.2,477.89%
PFIZER INC. 1.92% 37.23 Delayed Quote.0.30%
All news about ASTRAZENECA PLC
07:42aUK secures two million more doses of Moderna's COVID-19 vaccine
RE
05:55aASTRAZENECA : UK confirms H5N8 bird flu on English turkey farm
RE
11/28Serum Institute CEO sees AstraZeneca's COVID-19 vaccine as "very good" candid..
RE
11/28Serum Institute CEO sees AstraZeneca's COVID-19 vaccine as "very good" candid..
RE
11/28UK regulator set to approve COVID-19 vaccine next week - FT
RE
11/28India's Modi visits key vaccine facilities as COVID-19 cases surge
RE
11/28UK appoints vaccines minister to oversee COVID inoculations
AQ
11/28India's Modi visits key vaccine facilities as COVID-19 case load surges
RE
11/28Oil prices post weekly gain ahead of OPEC+ meeting
RE
11/27SALESFORCE, DELTA AIR LINES, BEST BU : Stocks That Defined the Week
DJ
More news
Financials (USD)
Sales 2020 26 512 M - -
Net income 2020 2 998 M - -
Net Debt 2020 13 181 M - -
P/E ratio 2020 43,5x
Yield 2020 2,72%
Capitalization 136 B 136 B -
EV / Sales 2020 5,62x
EV / Sales 2021 4,89x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 121,49 $
Last Close Price 103,45 $
Spread / Highest target 50,3%
Spread / Average Target 17,4%
Spread / Lowest Target -36,2%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC2.14%135 908
DAIICHI SANKYO COMPANY, LIMITED56.60%72 682
JIANGSU HENGRUI MEDICINE CO., LTD.17.92%69 850
YUNNAN BAIYAO GROUP CO.,LTD7.23%18 673
ORION OYJ-3.10%6 712
SWEDISH ORPHAN BIOVITRUM AB1.42%5 440